Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Spark Capital Advisors(India) Private Limited
$35.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aurobindo Pharma Ltd Receives Final Approvals For Oxacillin Injections


Sunday, 20 Jan 2013 10:44pm EST 

Aurobindo Pharma Ltd announced that it has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Oxacillin for Injection USP, packaged in 1g and 2g vials (ANDA 201539) and Oxacillin for Injection USP 10g/Vial Pharmacy Bulk Package (ANDA 201538). The products are ready for launch. Oxacillin for Injection USP is a sterile semisynthetic penicillin (SSP) indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. These ANDAs have been approved out of Unit XII formulation facility in Hyderabad, India and will be marketed and sold by Aurobindo's US subsidiary AuroMedics Pharma LLC. 

Company Quote

1076.35
27.75 +2.65%
5:22am EST